ABEO: First Patient Treated with Zevaskyn Pushed to 4Q25 Following Assay Optimization
On November 12, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the third quarter of 2025 and provided a business...
281 Views
ABEO: First Patient Treatment with Zevaskyn Expected in 3Q25
On August 14, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the second quarter of 2025 and provided a business...
184 Views
ABEO: Sells Priority Review Voucher for 155 Million
On May 15, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the first quarter of 2025 and provided a business...
315 Views
ABEO: Zevaskyn Approved by FDA Raising Valuation to 11
On April 29, 2025, Abeona Therapeutics, Inc. (ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene...
391 Views
ABEO: Countdown to PDUFA Date of April 29, 2025
On March 20, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the fourth quarter and full year of 2024 and provided a...
344 Views